Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crofelemer in Pediatric Participants With Microvillus Inclusion Disease (MVID)
NCT06721871Phase 3Active, not recruiting
- Sponsor
- Napo Pharmaceuticals
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of crofelemer in microvillus inclusion disease (MVID), sponsored by Napo Pharmaceuticals. Started May 2025; status: active, not recruiting.
02
Drugs
crofelemer
03
Conditions
microvillus inclusion disease (MVID)
Beyond the preview
Go deeper on NCT06721871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06721871.